PURPOSE: First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases. MATERIALS AND METHODS: Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated. RESULTS: In total, 37% of the metastases were bone metastases, 48% were pelvic nodal metastases, and 15% were nodal metastases outside of the pelvis. After PSMA-guided radiotherapy, a biochemical response was detected in 83% of the cohort. A statistically significant decrease in the standard uptake value (SUV) was seen in irradiated metastases. After a median follow-up of 26 months, the 3-year OS and bPFS were 84% and 55%, respectively. The median time of ADT-free survival was 13.5 months. A better clinical outcome was observed for patients receiving concomitant ADT or more than 24 fractions of radiation. CONCLUSION: PSMA-guided radiotherapy is a promising therapeutic approach with excellent infield control for men with oligorecurrent prostate carcinoma. However, prospective, randomized trials are necessary to determine if this approach confers a survival advantage.
PURPOSE: First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases. MATERIALS AND METHODS: Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated. RESULTS: In total, 37% of the metastases were bone metastases, 48% were pelvic nodal metastases, and 15% were nodal metastases outside of the pelvis. After PSMA-guided radiotherapy, a biochemical response was detected in 83% of the cohort. A statistically significant decrease in the standard uptake value (SUV) was seen in irradiated metastases. After a median follow-up of 26 months, the 3-year OS and bPFS were 84% and 55%, respectively. The median time of ADT-free survival was 13.5 months. A better clinical outcome was observed for patients receiving concomitant ADT or more than 24 fractions of radiation. CONCLUSION: PSMA-guided radiotherapy is a promising therapeutic approach with excellent infield control for men with oligorecurrent prostate carcinoma. However, prospective, randomized trials are necessary to determine if this approach confers a survival advantage.
Entities:
Keywords:
Metastases; OS; PET; PSMA; Prostate cancer; SUV
Authors: Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Giri Sulur; Yesenia Luna; Susan Li; Suneel Mundle; Kim N Chi Journal: Lancet Oncol Date: 2019-04-12 Impact factor: 41.316
Authors: Christina Bluemel; Markus Krebs; Bülent Polat; Fränze Linke; Matthias Eiber; Samuel Samnick; Constantin Lapa; Michael Lassmann; Hubertus Riedmiller; Johannes Czernin; Domenico Rubello; Thorsten Bley; Saskia Kropf; Hans-Juergen Wester; Andreas K Buck; Ken Herrmann Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: M Picchio; G Berardi; A Fodor; E Busnardo; C Crivellaro; G Giovacchini; C Fiorino; M Kirienko; E Incerti; C Messa; L Gianolli; N Di Muzio Journal: Eur J Nucl Med Mol Imaging Date: 2014-03-06 Impact factor: 9.236
Authors: Felix Dietlein; Carsten Kobe; Melanie Hohberg; Boris D Zlatopolskiy; Philipp Krapf; Heike Endepols; Philipp Täger; Jochen Hammes; Axel Heidenreich; Thorsten Persigehl; Bernd Neumaier; Alexander Drzezga; Markus Dietlein Journal: J Nucl Med Date: 2019-10-18 Impact factor: 10.057
Authors: Stefan A Koerber; Gerald Stach; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Peter L Choyke; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: J Nucl Med Date: 2019-07-13 Impact factor: 11.082
Authors: Karel Decaestecker; Gert De Meerleer; Bieke Lambert; Louke Delrue; Valérie Fonteyne; Tom Claeys; Filip De Vos; Wouter Huysse; Arne Hautekiet; Gaethan Maes; Piet Ost Journal: Radiat Oncol Date: 2014-06-12 Impact factor: 3.481
Authors: Julian M M Rogasch; Ronald Boellaard; Lucy Pike; Peter Borchmann; Peter Johnson; Jürgen Wolf; Sally F Barrington; Carsten Kobe Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-14 Impact factor: 9.236
Authors: Pierpaolo Alongi; Riccardo Laudicella; Helena Lanzafame; Andrea Farolfi; Paola Mapelli; Maria Picchio; Irene A Burger; Andrei Iagaru; Fabio Minutoli; Laura Evangelista Journal: Cancers (Basel) Date: 2022-03-31 Impact factor: 6.639